A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in 89bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 34,100 shares of ETNB stock, worth $271,095. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,100
Previous 20,100 69.65%
Holding current value
$271,095
Previous $161,000 56.52%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.36 - $9.66 $3.29 Million - $4.32 Million
447,645 Added 21.22%
2,556,727 $18.9 Million
Q2 2024

Aug 14, 2024

BUY
$7.31 - $10.9 $3.94 Million - $5.88 Million
539,540 Added 34.38%
2,109,082 $16.9 Million
Q1 2024

May 15, 2024

SELL
$8.13 - $13.77 $4.95 Million - $8.38 Million
-608,797 Reduced 27.95%
1,569,542 $18.3 Million
Q4 2023

Feb 14, 2024

BUY
$6.66 - $16.03 $4.49 Million - $10.8 Million
674,330 Added 44.84%
2,178,339 $24.3 Million
Q3 2023

Nov 14, 2023

BUY
$15.06 - $19.41 $6.32 Million - $8.15 Million
419,653 Added 38.7%
1,504,009 $23.2 Million
Q2 2023

Aug 14, 2023

SELL
$14.15 - $22.03 $11.6 Million - $18.1 Million
-819,999 Reduced 43.06%
1,084,356 $20.5 Million
Q1 2023

May 15, 2023

BUY
$10.48 - $16.94 $10 Million - $16.2 Million
954,043 Added 100.39%
1,904,355 $29 Million
Q4 2022

Feb 14, 2023

SELL
$5.52 - $12.73 $1.02 Million - $2.34 Million
-184,110 Reduced 16.23%
950,312 $12.1 Million
Q3 2022

Nov 14, 2022

BUY
$3.02 - $7.0 $213,870 - $495,726
70,818 Added 6.66%
1,134,422 $6.57 Million
Q2 2022

Aug 15, 2022

BUY
$2.09 - $4.02 $1.36 Million - $2.61 Million
650,485 Added 157.46%
1,063,604 $3.42 Million
Q1 2022

May 16, 2022

BUY
$3.45 - $14.99 $492,366 - $2.14 Million
142,715 Added 52.78%
413,119 $1.56 Million
Q4 2021

Feb 14, 2022

SELL
$11.15 - $19.66 $216,867 - $382,387
-19,450 Reduced 6.71%
270,404 $3.53 Million
Q3 2021

Nov 15, 2021

SELL
$14.91 - $21.31 $2.97 Million - $4.24 Million
-198,911 Reduced 40.7%
289,854 $5.68 Million
Q2 2021

Aug 16, 2021

SELL
$17.42 - $28.0 $332,756 - $534,856
-19,102 Reduced 3.76%
488,765 $9.14 Million
Q1 2021

May 17, 2021

BUY
$20.22 - $26.73 $362,221 - $478,841
17,914 Added 3.66%
507,867 $12 Million
Q4 2020

Feb 16, 2021

BUY
$23.16 - $28.08 $11.1 Million - $13.5 Million
480,519 Added 5093.48%
489,953 $11.9 Million
Q3 2020

Nov 16, 2020

BUY
$24.34 - $38.82 $229,623 - $366,227
9,434 New
9,434 $242,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $370M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.